Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 28/02/20 at 12:06pm

The coronavirus continues to spread across the globe as the US launch their first trials for Gilead's ebola drug remdesivir in treating COVID-19. This comes at a time where US domestic supplies of 150 drugs are under threat from the epidemic.

In other news, MIT researchers have identified a new antibiotic compound using a machine-learning algorithm while Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore apps for stroke detection.

10. FDA advisory committee narrowly backs Eli Lilly's Cyramza combo for metastatic EGFR+ NSCLC

Eli Lilly’s Cyramza (ramucirumab) has edged closer to US approval after it scored a recommendation from the FDA’s Oncologic Drugs Advisory Committee (ODAC).

9. New Johnson & Johnson study aiming to add stroke detection to Apple Watch

Johnson & Johnson announced that Janssen Pharmaceuticals will work in collaboration with Apple to explore apps for stroke detection.

8. NICE rejects Roche's Polivy combo in relapsed or refractory diffuse large B-cell lymphoma

It has been revealed that UK drug watchdog NICE has chosen to reject Roche’s Polivy (polatuzumab vedotin), used alongside rituximab and bendamustine, in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adult patients who are not eligible for haematopoietic stem cell transplant.

7.US Judge rules that a decade of unpublished trial results must be made public

A federal judge in New York’s Southern District has ruled that 10 years of unpublished clinical trial data must now be made public – a judgement which could have vast implications for possibly over 1,000 unpublished studies between 2007 and 2017.

6. Scotland's life sciences sector on track to break $8 billion by 2025

A new report from the Scottish Government has revealed that the country’s life sciences sector is on track to breeze past its turnover target of $8 billion by the year 2025, thanks to strong and consistent growth over the past seven years.

5. New antibiotic discovered by AI for the first time

MIT researchers have identified a new antibiotic compound using a machine-learning algorithm.

4. US domestic supply of 150 drugs under threat from coronavirus outbreak

Disruption to the US drug production pipeline from the coronavirus could hurt its domestic supply of 150 drugs.

3. Clover Biopharmaceuticals partners up with GSK to accelerate coronavirus vaccine development

Chinese biotech firm Clover Biopharmaceuticals has joined the race to develop interventions against the ongoing coronavirus outbreak with the announcement that it has partnered up with GlaxoSmithKline (GSK) to aid in development of its protein-based “COVID-19 S-Trimer” vaccine.

2. First US coronavirus trial launched into Gilead's remdesivir

The first US clinical trial investigating a treatment for the COVID-19 coronavirus has been launched by the US National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

1. FDA approves first adjuvanted quadrivalent flu vaccine in over-65s

The FDA has just authorised its first adjuvanted quadrivalent influenza vaccine, it has been announced. Seqirus’ Fluad Quadrivalent (influenza vaccine, adjuvanted) has been approved in the US to for the prevention of seasonal vaccine in patients over the age of 65.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches